|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Commercial and Pipeline Insight: HRT for Menopausal Symptoms
In 2007, the market value of HRT for menopausal symptoms saw its first upturn since the Women’s Health initiative (WHI) study results in 2002; highly publicized findings which linked HRT to cancer and cardiovascular safety risks. The recent growt
Pipeline/Commercial Insight: Antihypertensives
Analysis of the antihypertensives pipeline and the competitive landscape across seven major markets. Analysis of the threats to currently marketed drugs. Assessment of the opportunity available to novel agents, including Novartis’s Tekturna.
Commercial and Pipeline Insight: ADHD
The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the
Pipeline and Commercial Insight: Schizophrenia
This report provides full analysis of the current and future schizophrenia drug market, with indication-specific sales value and volume forecasts to 2017 of branded, generic, and key pipeline drugs in the US, Japan, and five major European markets.
Commercial and Pipeline Insight: Opioids
This report provides full analysis of the current and future Opioid market, with indication-specific sales forecasts to 2017 of marketed brands, generics, and key pipeline drugs in the US, 5EU, and Japan.
Pipeline and Commercial Insight: Neuropathic Pain
The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017. The growth in the market is spurred on by the uptake of Pfizer’s Lyrica (pregabalin), forecast to reach almost $3 billion in
Pipeline and Commercial Insight: Alzheimers Disease
This report provides full analysis of the future Alzheimer’s disease (AD) market, with four indication- and region-specific scenario forecasts evaluating the commercial potential of pipeline and marketed drugs.
Commercial and Pipeline Insight: Fibromyalgia
This report provides full analysis of the current and future fibromyalgia market, with indication-specific forecasts to 2017 of branded, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).
Pipeline and Commercial Insight: Urinary Incontinence
The UI market is set to continue to grow over the next 6 years, reaching over $2.5 billion in 2012, a 68% increase from 2006. Lifecycle management strategies, novel formulations and follow-on products will drive the majority of this growth, with key br
Results 1 - 10 of 10
|
Latest News
|
Expert Views: Key decision makers will shape the biosimilars landscape |
|
Read more...
|
|
Expert Views: Is there an alternative to HRT for menopausal relief? |
|
Read more...
|
|
Market Research Update W45 2008 |
|
Read more...
|
|
|
